A new publication involving elamipretide appeared on June 22, 2026. The paper, titled "Therapeutic targeting of mitochondrial dysfunction in heart failure: a systematic review & meta-analysis of clinical outcomes," was published in Frontiers in Cardiovascular Medicine.
The publication is described as a systematic review and meta-analysis examining clinical outcomes related to therapies targeting mitochondrial dysfunction in heart failure. Elamipretide is included among the compounds discussed in this context.
This entry reflects only the publication record itself. No specific findings, results, or conclusions from the review are detailed here beyond its title and journal placement. Readers interested in the full scope of the analysis should consult the original article directly through the source link provided.
Elamipretide remains an approved compound, and this publication represents a new addition to the scientific literature referencing its use in the context of mitochondrial-targeted heart failure research. As with any systematic review, the value of such work often lies in its synthesis of existing clinical data across multiple studies rather than new experimental results.
For more background on elamipretide, including its regulatory status and general profile, readers can refer to the compound overview.